Search

Your search keyword '"T Hovi"' showing total 41 results

Search Constraints

Start Over You searched for: Author "T Hovi" Remove constraint Author: "T Hovi" Topic antibodies, viral Remove constraint Topic: antibodies, viral
41 results on '"T Hovi"'

Search Results

1. An enterovirus strain isolated from diabetic child belongs to a genetic subcluster of echovirus 11, but is also neutralised with monotypic antisera to coxsackievirus A9.

2. Enterovirus infection may induce humoral immune response reacting with islet cell autoantigens in humans.

3. Virological and serological analysis of rhinovirus infections during the first two years of life in a cohort of children.

4. Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine.

5. Problems with biotin-labelled virions as probes in poliovirus-specific mu-capture-IgM assays.

6. Enterovirus infections as a possible risk factor for myocardial infarction.

7. Etiology of measles- and rubella-like illnesses in measles, mumps, and rubella-vaccinated children.

8. Induction of neutralizing antibodies by synthetic peptides representing the C terminus of coxsackievirus A9 capsid protein VP1.

9. Expression of Coxsackievirus B4 proteins VP0 and 2C in Escherichia coli and generation of virus protein recognizing antisera.

10. Isolation of escape mutants of a hybrid poliovirus with the aid of insert-specific polyclonal antibodies.

11. Twenty-one patients with strictly defined postpoliomyelitis syndrome: no poliovirus-specific IgM antibodies in the cerebrospinal fluid.

12. Intrathecal immune response and virus-specific immunoglobulin M antibodies in laboratory diagnosis of acute poliomyelitis.

13. Peptide antisera targeted to a conserved sequence in poliovirus capsid VP1 cross-react widely with members of the genus Enterovirus.

14. Antigenic regions of poliovirus type 3/Sabin capsid proteins recognized by human sera in the peptide scanning technique.

15. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice.

16. Good seroresponse to enhanced-potency inactivated poliovirus vaccine in patients on chronic dialysis.

17. Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine.

18. Determination of mumps and influenza antibodies by haemolysis-in-gel.

19. OC43 strain-related coronavirus antibodies in different age groups.

20. Antibodies to human coronavirus OC43 measured by radial haemolysis in gel.

21. Radiometric cytolysis inhibition assay, a new rapid test for neutralizing antibodies to intact and trypsin-cleaved poliovirus.

22. Enzyme immunoassay, complement fixation and hemagglutination inhibition tests in the diagnosis of influenza A and B virus infections. Purified hemagglutinin in subtype-specific diagnosis.

23. Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin.

24. Immunoglobulin class-specific serological responses to adenovirus in respiratory infections of young adult men.

25. Kinetics of specific IgA, IgD, IgE, IgG, and IgM antibody responses in rubella.

26. The outbreak of poliomyelitis in Finland in 1984-1985: significance of antigenic variation of type 3 polioviruses and site specificity of antibody responses in antipolio immunizations.

27. Coronavirus infections of man associated with diseases other than the common cold.

28. Proportions of immunoglobulin isotypes in paralytic poliomyelitis and after vaccination.

30. Age-specific prevalence of antibodies to pyrimidine kinase enzymes of herpes simplex virus types 1 and 2, and of varicella zoster virus.

31. Age-specific prevalence of complement-fixing antibodies to sixteen viral antigens: a computer analysis of 58,500 patients covering a period of eight years.

32. Antibodies to coronaviruses OC43 and 229E in multiple sclerosis patients.

33. Virus excretion and strain specific antibody responses after oral poliovaccine in previously immunised children.

34. Good Seroresponse to Enhanced-Potency Inactivated Poliovirus Vaccine in Patients on Chronic Dialysis

35. Coxsackievirus immunization delays onset of diabetes in non-obese diabetic mice

36. Several different enterovirus serotypes can be associated with prediabetic autoimmune episodes and onset of overt IDDM. Childhood Diabetes in Finland (DiMe) Study Group

37. Peptide antisera targeted to a conserved sequence in poliovirus capsid VP1 cross-react widely with members of the genus Enterovirus

38. Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin

40. Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine

41. Radiometric cytolysis inhibition assay, a new rapid test for neutralizing antibodies to intact and trypsin-cleaved poliovirus

Catalog

Books, media, physical & digital resources